3-溴-4-氯苯甲酸甲酯 | 107947-17-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-溴-4-氯苯甲酸甲酯
• 中文别名: 3-溴-4-氯-苯甲酸甲酯
• 英文名称: methyl 3-bromo-4-chlorobenzoate
• 英文别名: methyl 4-chloro-3-bromobenzoate
• CAS: 107947-17-1
• 化学式: C₈H₆BrClO₂
• 分子量: 249.491
• InChiKey: CLRJXWANIVYEHH-UHFFFAOYSA-N

物化性质

• 沸点：
  280℃
• 密度：
  1.604
• 闪点：
  123℃

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2916399090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 3-bromo-4-chlorobenzoate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 3-bromo-4-chlorobenzoate
CAS number: 107947-17-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H6BrClO2
Molecular weight: 249.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-溴-4-氯苯甲酸甲酯 在 lithium aluminium tetrahydride 、 三乙胺 、 sodium iodide 作用下， 以 乙醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 丁酮 为溶剂， 反应 19.5h， 生成 2-(3-溴-4-氯苯基)乙腈
  参考文献：
  名称：

  Discovery of Potent and Selective SH2 Inhibitors of the Tyrosine Kinase ZAP-70

  摘要：

  A series of 1,2,4-oxadiazole analogues has been shown to be potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70, a potential therapeutic target for immune suppression. These compounds typically are 200-400-fold more potent than the native, monophosphorylated tetrapeptide sequences. When compared with the high-affinity xi-1-ITAM peptide (Ac-NQL-pYNELNLGRREE-pYDVLD-NH2, wherein pY refers to phosphotyrosine) some of the best 1,2,4-oxadiazole analogues are approximately 1 order of magnitude less active. This series of compounds displays an unprecedented level of selectivity over the closely related tyrosine kinase Syk, as well as other SH2-containing proteins such as Src and Grb2. Gel shift studies using a protein construct consisting only of C-terminal ZAP-70 SH2 demonstrate that these compounds can effectively engage this particular SH2 domain.

  DOI：

  10.1021/jm990229t
• 作为产物：
  描述：

  对氯苯甲酸甲酯 在 1,3-二溴-5,5-二甲基海因 、 3-硝基苯磺酸水合物 作用下， 反应 24.0h， 以85%的产率得到3-溴-4-氯苯甲酸甲酯
  参考文献：
  名称：

  具有吸电子取代基的芳烃催化亲电卤化

  摘要：

  芳烃的亲电卤化可能是制备芳基卤化物的最简单方法，芳基卤化物是农用化学品、材料和药物中的重要结构基序。然而，芳烃的亲核性被吸电子取代基削弱，其亲电子卤化反应通常需要苛刻的条件，导致底物范围和应用受到限制。因此，在温和条件下卤化含有吸电子基团（EWGs）和复杂生物活性化合物的芳烃一直是一个长期的挑战。在此，我们描述了在温和条件下具有吸电子取代基的芳烃的 Brønsted 酸催化卤化，为芳基卤化物提供了一种有效的方案。布朗斯台德酸与质子溶剂 1,1,1,3,3 的氢键，

  DOI：

  10.1021/jacs.2c06440

文献信息

• [EN] PIPERAZINE METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) NEGATIVE ALLOSTERIC MODULATORS FOR ANXIETY/DEPRESSION<br/>[FR] PIPÉRAZINE UTILISÉE EN TANT QUE MODULATEURS ALLOSTÉRIQUES NÉGATIFS AGISSANT SUR LE RÉCEPTEUR MÉTABOTROPIQUE DU GLUTAMATE DE TYPE 5 (MGLUR5)
  申请人：WYETH CORP

  公开号：WO2009143404A1

  公开（公告）日：2009-11-26

  The present teachings relate to piperazine metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators having Formula (I); wherein the constituent variables are as defined herein. The present teachings further relate to methods for the preparation of the compounds, and to methods for using the compounds for treatment of diseases and disorders including schizophrenia, paranoia, depression, manic-depressive illness and anxiety.

  本发明的教导涉及具有公式（I）的哌嗪代谢型谷氨酸受体5（mGluR5）负变构调节剂；其中构成变量如本文所述定义。本发明的教导还涉及制备这些化合物的方法，以及使用这些化合物治疗包括精神分裂症、偏执症、抑郁症、躁郁症和焦虑症等疾病和失调的方法。
• Photoinduced Hydroarylation and Cyclization of Alkenes with Luminescent Platinum(II) Complexes
  作者：Hanchao Cheng、Tsz‐Lung Lam、Yungen Liu、Zhou Tang、Chi‐Ming Che

  DOI：10.1002/anie.202011841

  日期：2021.1.18

  Photoinduced hydroarylation of alkenes is an appealing synthetic strategy for arene functionalization. Herein, we demonstrated that aryl radicals generated from electron‐deficient aryl chlorides/bromides could be trapped by an array of terminal/internal aryl alkenes in the presence of [Pt(O^N^C^N)] under visible‐light (410 nm) irradiation, affording anti‐Markovnikov hydroarylated compounds in up to

  烯烃的光诱导加氢芳基化是芳烃官能化的一种有吸引力的合成策略。在此，我们证明了在可见光下，[Pt（O ^ N ^ C ^ N）]存在下，电子不足的芳基氯化物/溴化物产生的芳基自由基可能被一系列末端/内部芳基烯烃捕获（410）。纳米）辐射，以高达95％的收率提供抗马氏化学水解的化合物。此外，还开发了一种用于[Pt（O ^ N ^ C ^ N）]催化的丙烯酰胺分子内光环化反应的化合物，以提供结构多样的3,4-二氢喹啉酮。
• ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
  申请人：BEIJING INNOCARE PHARMA TECH CO., LTD.

  公开号：US20190210997A1

  公开（公告）日：2019-07-11

  The present invention relates to an alkynyl-substituted heterocyclic compound acting as an FGFR inhibitor, a preparation method therefor and a medical use thereof. In particular, the present invention relates to a compound as shown in general formula (I) and a pharmaceutically acceptable salt thereof; a pharmaceutical composition including the compound or a pharmaceutically acceptable salt thereof; a method for treating and/or preventing FGFR-associated diseases, particularly tumors, by using the compound or a pharmaceutically acceptable salt thereof; and a preparation method for the compound or a pharmaceutically acceptable salt thereof. The present invention also relates to the use of the compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition including the compound or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating and/or preventing FGFR-associated diseases, particularly tumors, wherein the definition of each substituent group in general formula (I) is the same as that in the description.

  本发明涉及一种作为FGFR抑制剂的炔基取代杂环化合物，其制备方法及医药用途。具体而言，本发明涉及一种如一般式（I）所示的化合物及其药学上可接受的盐；包括该化合物或其药学上可接受的盐的药物组合物；通过使用该化合物或其药学上可接受的盐来治疗和/或预防FGFR相关疾病，特别是肿瘤的方法；以及该化合物或其药学上可接受的盐的制备方法。本发明还涉及使用该化合物或其药学上可接受的盐，或包括该化合物或其药学上可接受的盐的药物组合物来制备用于治疗和/或预防FGFR相关疾病，特别是肿瘤的药物，其中一般式（I）中每个取代基团的定义与描述中的相同。
• [EN] BROMODOMAIN INHIBITORS<br/>[FR] INHIBITEURS DE BROMODOMAINE
  申请人：ABBVIE INC

  公开号：WO2017177955A1

  公开（公告）日：2017-10-19

  The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R6, X1, and X2 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).

  本发明提供了一种具有以下结构的化合物（I），其中R1、R2、R3、R4、R6、X1和X2具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物在治疗疾病和病症中是有用的，包括炎症性疾病、癌症和艾滋病。还提供了包含化合物（I）的药物组合物。
• [EN] SUBSTITUTED (E)-N'-(1-PHENYLETHYLIDENE) BENZOHYDRAZIDE ANALOGS AS HISTONE DEMETHYLASE INHIITORS<br/>[FR] ANALOGUES DE (E)-N'-(1-PHÉNYLÉTHYLIDÈNE)BENZOHYDRAZIDE SUBSTITUÉS EN TANT QU'INHIBITEURS DE L'HISTONE DÉMÉTHYLASE
  申请人：UNIV UTAH RES FOUND

  公开号：WO2013025805A1

  公开（公告）日：2013-02-21

  In one aspect, the invention relates to substituted (E)-N'-(1- phenylethylidene)benzohydrazide analogs, derivatives thereof, and related compounds, which are useful as inhibitors of lysine-specific histone demethylase, including LSD1; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the LSD1. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  在一个方面，该发明涉及替代(E)-N'-(1-苯乙烯基)苯甲酰肼类似物，其衍生物以及相关化合物，这些化合物可用作赖氨酸特异性组蛋白去甲基化酶的抑制剂，包括LSD1；制备这些化合物的合成方法；包含这些化合物的药物组合物；以及使用这些化合物和组合物治疗与LSD1功能障碍相关的疾病的方法。本摘要旨在作为在特定领域进行搜索的扫描工具，并不旨在限制本发明。